UK researchers raise hopes of preserving fertility for women with cancerSeptember 23, 2001UK fertility experts have sounded a note of cautious optimism about the safety of preserving ovarian tissue and transplanting it back into women after cancer treatment. The optimism follows research reported today (Thursday 27 September) in Human Reproduction*, Europe's leading journal of reproductive medicine. It is the first reported non-test tube investigation in the world on the safety of grafting ovarian tissue from cancer patients. Women are often rendered infertile after drug or radiation treatment for cancer and scientists have for a long time been looking at ways to make it possible for women to have babies after they have recovered from treatment. For those who have no partner, young girls, or women who require immediate treatment, embryo freezing is not feasible. But another option - preserving ovarian tissue before treatment and transplanting it into the patient after treatment to reinstate fertility - in addition to being technically difficult, raises concerns that cancer cells lurking within the tissue could be re-introduced into the body with disastrous results. Now a study in mice by teams from Leeds and Manchester** led by Dr S. Samuel Kim has shown that fears about reintroducing cancer may be over-stated (at least in lymphoma patients) and that preserving ovarian tissue for later autotransplanation might be the viable option for young cancer patients anxious to preserve their fertility. The researchers grafted frozen and thawed ovarian tissue from 18 women with non-Hodgkins Lymphoma or Hodgkins Lymphomas (cancers of the lymph glands) into 30 immunodeficient mice. For controls, they grafted a disease-positive lymph node from a patient with a recurrent B-cell lymphoma, into three immunodeficient mice. None of the mice grafted with the ovarian tissue developed human lymphomas, but all three of the mice who received a graft from a diseased lymph node developed human B-cell lymphomas. Dr Kim said: "Ovarian tissue from cancer patients has been banked at many centres worldwide in preparation ultimately for transplantation back into patients after successful treatment. However, this step requires prior assurance that the tissue will not transmit disease after grafting. "This is the first reported in-vivo investigation of residual malignant disease in human ovarian tissue using a xenograft and this model, involving immunodeficient mice, may help to confirm clinical decisions about the risks of transplanting ovarian tissue back into cancer patients. "Our patients were deliberately selected for having high-risk disease and in the three years following tissue harvesting, half have died of lymphoma. So the study was based on worst-case scenarios of highly aggressive lymphomas that were likely to have already spread at the time the ovarian tissue was harvested." He said the immunodeficient mouse model was suitable for investigating the safety of ovarian transplantation, serving as a practical screen for the disease. While the study had focused on lymphoma, it was also an appropriate model for other cancers. However, he warned that the follow-up period was relatively short because of the naturally short life span of the mice and that efforts to develop new techniques to detect residual disease should continue. "Nevertheless, our findings are of immediate relevance to women with lymphomas who are considering banking ovarian tissue for fertility conservation and also to their physicians who need to provide them with appropriate advice. We can now be more optimistic about the application of ovarian cryopreservation and transplantation in cancer patients, although these reassuring findings should not be interpreted as an absolute indication of safety." Dr Kim said the research teams were now working on finding a method to screen cancer cells in ovarian tissue from patients before transplantation, and on laboratory and animal techniques to grow and mature primordial ovarian follicles. (ends) MW Communications |
|||||||||||||||||||||
| Related Lymphoma Current Events and Lymphoma News Articles New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Approved lymphoma drug shows promise in early tests against bone cancer A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). Exercise is good medicine for lymphoma patients A healthy dose of exercise is good medicine, even for lymphoma patients receiving chemotherapy, University of Alberta researchers have found. Childhood cancer survivors experience suicidal thoughts decades after diagnosis Adult survivors of childhood cancer have an increased risk for suicidal thoughts, even decades after their cancer treatments ended, according to a study led by Dana-Farber Cancer Institute scientists. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Studying cancer in pet dogs to find new treatments for human patients A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers. Scientists identify genetic cause of previously undefined primary immune deficiency disease Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. More Lymphoma Current Events and Lymphoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||